SCHWARZ PHARMA, INC. – Trademark Portfolio
Entity Type: 03
SCHWARZ PHARMA, INC. holds 24 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include EDEX, LEVBID, and LEVSIN. The owner is based in MEQUON, WI.
5600 WEST COUNTY LINE ROAD
MEQUON, WI 53092
Showing of trademarks Trademarks
Trademark Classifications
SCHWARZ PHARMA, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does SCHWARZ PHARMA, INC. have?
SCHWARZ PHARMA, INC. has 24 U.S. trademarks filed with the USPTO. Of these, 3 registered, 15 abandoned, 6 cancelled.
What trademark classes does SCHWARZ PHARMA, INC. file in?
SCHWARZ PHARMA, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are SCHWARZ PHARMA, INC.'s most well-known trademarks?
SCHWARZ PHARMA, INC.'s registered trademark portfolio includes well-known marks such as EDEX, LEVBID, and LEVSIN. These are among 3 currently registered trademarks in the portfolio.
What is SCHWARZ PHARMA, INC.'s trademark registration success rate?
SCHWARZ PHARMA, INC. has a 13% trademark registration rate, with 3 out of 24 resolved applications resulting in successful registration. Currently, 0 applications are pending review.